Multi-Omics-Driven Network Pharmacology and Experimental Validation Reveal the Molecular Mechanism of Bupi Yichang Pill in Treating Ulcerative Colitis Through Regulation of the PI3K/Akt/IKK/NF-κB Pathway.
Multi-omics analysis revealed that BYP restored gut microbiota dysbiosis, ameliorated bile acid and amino acid metabolism, and modulated the expression of inflammation- and barrier-related genes, providing both a mechanistic basis and pharmacological rationale for its traditional clinical use in UC management.